Pancreatic Cancer Research

ResearcherWenzhou Medical UniversityActive in the last 2 years

Yongheng Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3910-4731; OpenAlex author ID A5027551625. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
30
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 3 papers · 2024: 2 papers

Papers 18

  1. Nano-enabled regulation of DNA damage in tumor cells to enhance neoantigen-based pancreatic cancer immunotherapy. Co-author DOI 10.1016/j.biomaterials.2024.122710↗
  2. Smad4 regulates TGF-β1-mediated hedgehog activation to promote epithelial-to-mesenchymal transition in pancreatic cancer cells by suppressing Gli1 activity. Co-author DOI 10.1016/j.csbj.2024.03.010↗
  3. STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. Last author DOI 10.1016/j.intimp.2023.110709↗
  4. Phloretin-induced STAT3 inhibition suppresses pancreatic cancer growth and progression via enhancing Nrf2 activity. Last author DOI 10.1016/j.phymed.2023.154990↗
  5. S100A2 induces epithelial-mesenchymal transition and metastasis in pancreatic cancer by coordinating transforming growth factor β signaling in SMAD4-dependent … Last author DOI 10.1038/s41420-023-01661-1↗
  6. Rosmarinic Acid Decreases the Malignancy of Pancreatic Cancer Through Inhibiting Gli1 Signaling. Co-author DOI 10.1016/j.phymed.2021.153861↗
  7. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress p… Last author DOI 10.1038/s41419-022-04573-7↗
  8. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability an… Last author DOI 10.1038/s41419-022-04705-z↗
  9. Inhibition of STAT3Y705 phosphorylation by Stattic suppresses proliferation and induces mitochondrial-dependent apoptosis in pancreatic cancer cells. Last author DOI 10.1038/s41420-022-00922-9↗
  10. Quercetin suppresses pancreatic ductal adenocarcinoma progression via inhibition of SHH and TGF-β/Smad signaling pathways. Last author DOI 10.1007/s10565-020-09562-0↗
  11. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation. Last author DOI 10.18632/aging.203301↗
  12. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Co-author DOI 10.18632/aging.203725↗
  13. Pharmacological Inhibition of STAT3 Attenuates Pancreatic Cancer Cell Invasion and Migration By Interacting with TGF-Β/Smad Signaling Last author DOI 10.21203/rs.3.rs-1055773/v1↗
  14. The Anti-Dysenteric Drug Fraxetin Enhances Anti-Tumor Efficacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation Last author DOI 10.21203/rs.3.rs-125318/v1↗
  15. Molecular Mechanism of Pancreatic Stellate Cells Activation in Chronic Pancreatitis and Pancreatic Cancer. Co-author DOI 10.7150/jca.38616↗
  16. Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. Last author DOI 10.3892/or.2018.6241↗
  17. Sedum sarmentosum Bunge extract induces apoptosis and inhibits proliferation in pancreatic cancer cells via the hedgehog signaling pathway. Co-author DOI 10.3892/or.2016.4679↗
  18. Reversion of trichostatin A resistance via inhibition of the Wnt signaling pathway in human pancreatic cancer cells. Co-author DOI 10.3892/or.2014.3476↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hangcheng Guo · 11 shared papers, 2020–2024 · strength 1.61
  2. Yangyang Guo · 8 shared papers, 2020–2023 · strength 1.11
  3. Yanyi Xiao · 8 shared papers, 2020–2022 · strength 1.05
  4. Hengyue Zhu · 6 shared papers, 2020–2022 · strength 0.79
  5. Qiyu Zhang · 6 shared papers, 2020–2022 · strength 0.79
  6. Qinbo Chen · 3 shared papers, 2021–2023 · strength 0.45
  7. Jiawei Chen · 3 shared papers, 2021–2023 · strength 0.44
  8. Junjie Deng · 3 shared papers, 2020–2024 · strength 0.42
  9. Guihua Jin · 2 shared papers, 2020–2023 · strength 0.32
  10. Chunmei Wen · 2 shared papers, 2022–2023 · strength 0.32
  11. Jie Deng · 2 shared papers, 2022–2023 · strength 0.32
  12. Qingqing Ruan · 2 shared papers, 2022–2023 · strength 0.32
  13. Miaomiao Lin · 2 shared papers, 2022 · strength 0.30
  14. Chunjing Lin · 1 shared paper, 2024 · strength 0.20
  15. Bicheng Chen · 3 shared papers, 2014–2018 · strength 0.20
  16. Jilong Wang · 1 shared paper, 2024 · strength 0.19
  17. Guogang Li · 1 shared paper, 2023 · strength 0.18
  18. Bicheng Chen · 1 shared paper, 2020 · strength 0.15
  19. Xu Zheng · 1 shared paper, 2022 · strength 0.15
  20. Xiang Zhou · 1 shared paper, 2022 · strength 0.15
  21. Wei‐Ming Wang · 1 shared paper, 2022 · strength 0.15
  22. Xiangyang Lin · 1 shared paper, 2021 · strength 0.13
  23. Yunfeng Shan · 1 shared paper, 2021 · strength 0.13
  24. Mengtao Zhou · 2 shared papers, 2014–2018 · strength 0.13
  25. Xing Zhang · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.